Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$13.35 -0.8%	$14.18	$10.96 ▼ $32.97	$703.17M	2.28	1.20 million shs	428,965 shs
FTRE Fortrea	$9.98 -0.9%	$7.10	$3.97 ▼ $25.28	$903.46M	1.88	2.32 million shs	838,050 shs
PNTG The Pennant Group	$24.31 -2.1%	$24.39	$21.18 ▼ $37.13	$840.03M	1.31	256,993 shs	329,011 shs
VMD Viemed Healthcare	$6.66 -0.8%	$6.79	$5.93 ▼ $9.81	$258.51M	1.38	178,846 shs	79,898 shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	+0.82%	-2.89%	+12.36%	-33.02%	-50.97%
FTRE Fortrea	-2.42%	+0.60%	+53.04%	+85.45%	-50.30%
PNTG The Pennant Group	+1.31%	+3.63%	-4.50%	-10.20%	-23.29%
VMD Viemed Healthcare	-2.33%	-1.47%	-5.49%	-0.59%	-9.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$13.35 -0.8%	$14.18	$10.96 ▼ $32.97	$703.17M	2.28	1.20 million shs	428,965 shs
FTRE Fortrea	$9.98 -0.9%	$7.10	$3.97 ▼ $25.28	$903.46M	1.88	2.32 million shs	838,050 shs
PNTG The Pennant Group	$24.31 -2.1%	$24.39	$21.18 ▼ $37.13	$840.03M	1.31	256,993 shs	329,011 shs
VMD Viemed Healthcare	$6.66 -0.8%	$6.79	$5.93 ▼ $9.81	$258.51M	1.38	178,846 shs	79,898 shs

7 Stocks to Ride The A.I. Megaboom

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	+0.82%	-2.89%	+12.36%	-33.02%	-50.97%
FTRE Fortrea	-2.42%	+0.60%	+53.04%	+85.45%	-50.30%
PNTG The Pennant Group	+1.31%	+3.63%	-4.50%	-10.20%	-23.29%
VMD Viemed Healthcare	-2.33%	-1.47%	-5.49%	-0.59%	-9.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDNA CareDx	2.57	Moderate Buy	$27.67	107.32% Upside
FTRE Fortrea	2.17	Hold	$11.50	15.29% Upside
PNTG The Pennant Group	2.60	Moderate Buy	$34.40	41.51% Upside
VMD Viemed Healthcare	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VMD, FTRE, PNTG, and CDNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2025	FTRE Fortrea	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$7.00 ➝ $9.50
9/4/2025	PNTG The Pennant Group	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$40.00
9/3/2025	FTRE Fortrea	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$9.00 ➝ $14.00
8/26/2025	CDNA CareDx	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform
8/14/2025	PNTG The Pennant Group	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$31.00 ➝ $29.00
8/8/2025	CDNA CareDx	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$19.00 ➝ $14.00
8/8/2025	FTRE Fortrea	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	In-Line	$5.00 ➝ $7.00
8/7/2025	FTRE Fortrea	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underweight	$5.00 ➝ $6.00
8/4/2025	FTRE Fortrea	Baird R W Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/4/2025	FTRE Fortrea	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$7.00 ➝ $9.00
7/18/2025	CDNA CareDx	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $26.00

(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDNA CareDx	$333.79M	2.13	$1.36 per share	9.81	$7.06 per share	1.89
FTRE Fortrea	$2.73B	0.33	$1.52 per share	6.57	$15.19 per share	0.66
PNTG The Pennant Group	$798.92M	1.05	$0.91 per share	26.58	$9.08 per share	2.68
VMD Viemed Healthcare	$240.88M	1.07	$0.91 per share	7.30	$3.41 per share	1.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDNA CareDx	$52.55M	$1.02	12.95	N/A	N/A	17.97%	18.03%	12.88%	11/3/2025 (Estimated)
FTRE Fortrea	-$328.50M	-$11.38	N/A	7.79	N/A	-37.57%	5.25%	1.72%	11/14/2025 (Estimated)
PNTG The Pennant Group	$22.56M	$0.78	31.16	27.62	2.02	3.36%	9.85%	4.04%	11/5/2025 (Estimated)
VMD Viemed Healthcare	$11.27M	$0.34	19.60	∞	N/A	5.80%	10.38%	7.88%	11/5/2025 (Estimated)

Latest VMD, FTRE, PNTG, and CDNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	CDNA CareDx	$0.12	-$0.16	-$0.28	-$0.16	$90.72 million	$90.51 million
8/6/2025	Q2 2025	FTRE Fortrea	$0.06	$0.19	+$0.13	-$4.14	$631.61 million	$710.30 million
8/6/2025	Q2 2025	VMD Viemed Healthcare	$0.0850	$0.08	-$0.0050	$0.08	$63.50 million	$63.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
FTRE Fortrea	N/A	N/A	N/A	N/A	N/A
PNTG The Pennant Group	N/A	N/A	N/A	N/A	N/A
VMD Viemed Healthcare	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDNA CareDx	N/A	3.30	3.00
FTRE Fortrea	1.87	1.02	1.02
PNTG The Pennant Group	0.11	1.21	1.21
VMD Viemed Healthcare	0.02	1.48	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDNA CareDx	N/A
FTRE Fortrea	N/A
PNTG The Pennant Group	85.88%
VMD Viemed Healthcare	74.24%

Insider Ownership

Company	Insider Ownership
CDNA CareDx	4.40%
FTRE Fortrea	0.38%
PNTG The Pennant Group	5.40%
VMD Viemed Healthcare	20.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDNA CareDx	740	53.23 million	50.89 million	Optionable
FTRE Fortrea	15,500	90.80 million	90.46 million	Optionable
PNTG The Pennant Group	7,000	34.56 million	32.70 million	Optionable
VMD Viemed Healthcare	1,179	38.79 million	31.03 million	Not Optionable

VMD, FTRE, PNTG, and CDNA Headlines

Recent News About These Companies

Punch & Associates Investment Management Inc. Sells 265,651 Shares of Viemed Healthcare, Inc. $VMD

September 9 at 5:31 AM | marketbeat.com

Trexquant Investment LP Has $717,000 Stock Holdings in Viemed Healthcare, Inc. $VMD

September 9 at 3:33 AM | marketbeat.com

Nuveen LLC Acquires New Position in Viemed Healthcare, Inc. $VMD

September 4, 2025 | marketbeat.com

Paradigm Capital Management Inc. NY Sells 100,000 Shares of Viemed Healthcare, Inc. $VMD

September 2, 2025 | marketbeat.com

Gabelli Funds LLC Acquires 45,837 Shares of Viemed Healthcare, Inc. $VMD

September 2, 2025 | marketbeat.com

Jerome Cambre Sells 4,880 Shares of Viemed Healthcare, Inc. (NASDAQ:VMD) Stock

August 16, 2025 | marketbeat.com

Insider Selling: Viemed Healthcare, Inc. (NASDAQ:VMD) President Sells 50,090 Shares of Stock

August 15, 2025 | marketbeat.com

Michael Moore Sells 50,090 Shares of Viemed Healthcare, Inc. (NASDAQ:VMD) Stock

August 14, 2025 | insidertrades.com

Viemed Healthcare, Inc. (NASDAQ:VMD) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

Viemed Healthcare (NASDAQ:VMD) Posts Quarterly Earnings Results, Meets Estimates

August 10, 2025 | marketbeat.com

Viemed Healthcare, Inc. (VMD) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Viemed VMD Q2 2025 Earnings Call Transcript

August 7, 2025 | fool.com

Viemed (VMD) Q2 Revenue Rises 15%

August 6, 2025 | fool.com

Viemed Healthcare Achieves Record Q2 2025 Revenues and Expands Guidance

August 6, 2025 | msn.com

Viemed Healthcare, Inc.: Viemed Healthcare Announces Second Quarter 2025 Financial Results

August 6, 2025 | finanznachrichten.de

Viemed Healthcare Announces Second Quarter 2025 Financial Results

August 6, 2025 | accessnewswire.comA

Viemed Healthcare Announces Second Quarter 2025 Earnings Conference Call Details

July 22, 2025 | accessnewswire.comA

Lafayette’s Viemed completes $26 million acquisition of Illinois medical equipment firm

July 9, 2025 | theadvertiser.comT

Viemed officially adds Lehan’s to family

July 7, 2025 | hmenews.comH

Viemed Completes Acquisition of Lehan's Medical Equipment Anticipates Updating its Full Year 2025 Outlook for the Acquisition with Second Quarter 2025 Financial Results

July 2, 2025 | accessnewswire.comA

Insider Selling: Viemed Healthcare, Inc. (NASDAQ:VMD) Director Sells 8,852 Shares of Stock

July 1, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VMD, FTRE, PNTG, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

$13.34 -0.11 (-0.78%)

As of 01:53 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Fortrea NASDAQ:FTRE

$9.98 -0.10 (-0.94%)

As of 01:53 PM Eastern

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

The Pennant Group NASDAQ:PNTG

$24.31 -0.52 (-2.10%)

As of 01:53 PM Eastern

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.

Viemed Healthcare NASDAQ:VMD

$6.66 -0.06 (-0.82%)

As of 01:53 PM Eastern

Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VMD, FTRE, PNTG, and CDNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VMD, FTRE, PNTG, and CDNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VMD, FTRE, PNTG, and CDNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VMD, FTRE, PNTG, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

Fortrea NASDAQ:FTRE

The Pennant Group NASDAQ:PNTG

Viemed Healthcare NASDAQ:VMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VMD, FTRE, PNTG, and CDNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VMD, FTRE, PNTG, and CDNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VMD, FTRE, PNTG, and CDNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VMD, FTRE, PNTG, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

Fortrea NASDAQ:FTRE

The Pennant Group NASDAQ:PNTG

Viemed Healthcare NASDAQ:VMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools